Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Institutional and Insider Ownership
52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Whitehawk Therapeutics and Grifols”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | N/A | N/A | -$20.60 million | ($1.12) | -2.79 |
| Grifols | $8.51 billion | 0.68 | $454.82 million | $0.19 | 44.79 |
Grifols has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Whitehawk Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Profitability
This table compares Whitehawk Therapeutics and Grifols’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| Grifols | 5.54% | 6.21% | 2.39% |
Analyst Ratings
This is a breakdown of current recommendations for Whitehawk Therapeutics and Grifols, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
| Grifols | 1 | 2 | 0 | 0 | 1.67 |
Whitehawk Therapeutics presently has a consensus price target of $8.33, suggesting a potential upside of 167.09%. Grifols has a consensus price target of $9.00, suggesting a potential upside of 5.76%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Whitehawk Therapeutics is more favorable than Grifols.
Summary
Grifols beats Whitehawk Therapeutics on 7 of the 13 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
